Brief: Cytodyn Says 49 COVID-19 Patients Have Enrolled For Treatment With Leronlimab Through eIND

Cytodyn

04/05/2020 13:10

May 4 (Reuters) - Cytodyn Inc  CYDY.PK :
    * FDA APPROVES 54 EMERGENCY INDS FOR LERONLIMAB TREATMENT OF
CORONAVIRUS – CYTODYN REQUESTS COMPASSIONATE USE FROM FDA FOR
COVID-19 PATIENTS NOT ELIGIBLE FOR PARTICIPATION IN TWO ONGOING
CLINICAL TRIALS IN U.S. – CYTODYN TARGETS ENROLLMENT COMPLETION
FOR IT
    * CYTODYN INC - 49 COVID-19 PATIENTS HAVE ENROLLED FOR
TREATMENT
WITH LERONLIMAB THROUGH EIND
    * CYTODYN INC - 4 OUT OF 11 CRITICALLY ILL PATIENTS WITH
PRE-EXISTING CONDITIONS SURVIVED AFTER TREATMENT WITH LERONLIMAB
    * CYTODYN INC - OF NEXT 38 PATIENTS TREATED WITH LERONLIMAB,
MANY
WERE EXTUBATED, IMPROVED, OR WERE DISCHARGED

Source text for Eikon:  ID:nGNX4G4LS1 
Further company coverage:  CYDY.PK 

 ((Reuters.Briefs@thomsonreuters.com;))